Shots:
- SNAP Biosciences & Monarch Therapeutics have entered into a licensing agreement for Monarch’s small molecule adaptor tech to develop & commercialize SNAP’s Snap-Car NK cell therapy platform in oncology
- Financial terms remain undisclosed but incl. an upfront licensing payment, future development milestones, with net sales-based royalties
- Monarch’s tech enables SNAP-CAR cells to be directed by small molecule-based adaptors, allowing simultaneous targeting of multiple tumor antigens & real-time activity modulation, with improved manufacturing & regulatory pathways
Ref: Globenewswire| Image: Snap Bio & Monarch Therapeutics| Press Release
Related News:- Biogen Joins Forces with City Therapeutics to Develop Novel RNAi Therapies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
